Everything points to a partnership/buyout. Viacyte suffered a major setback and is now unreliable, precisely the reason why J & J hedged their bet with Viacyte. Let's see what J & J does with PharmaCyte, whose technology has already proven successful in numerous clinical trials and is preparing to enter a pivotal trial for FDA marketing approval.